Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 14/20 | 0.69 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.67 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.64 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.64 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.64 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.64 |
| ▸ | LDHA | P00338 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | FBP1 | P09467 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.64 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23780814 | 1.00 | DNPH1 (0.69) | DNPH1P2RY12TAS1R3TAS1R1P2RY2 | |
| SCHEMBL23787292 | 1.00 | DNPH1 (0.69) | DNPH1P2RY12TAS1R3TAS1R1P2RY2 | |
| SCHEMBL23787291 | 1.00 | DNPH1 (0.69) | DNPH1P2RY12TAS1R3TAS1R1P2RY2 | |
| SCHEMBL23780817 | 1.00 | DNPH1 (0.69) | DNPH1P2RY12TAS1R3TAS1R1P2RY2 | |
| SCHEMBL23780815 | 0.86 | ADORA3 (0.66) | ADORA1SMN1; SMN2 | |
| SCHEMBL23780820 | 0.86 | ADORA3 (0.66) | ADORA1SMN1; SMN2 | |
| SCHEMBL23780816 | 0.86 | ADORA3 (0.66) | ADORA1SMN1; SMN2 | |
| SCHEMBL23787289 | 0.86 | ADORA3 (0.66) | ADORA1SMN1; SMN2 | |
| SCHEMBL23787290 | 0.86 | ADORA3 (0.66) | ADORA1SMN1; SMN2 | |
| SCHEMBL23780819 | 0.86 | ADORA3 (0.66) | ADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 899 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698663-A1 | GENOME EDITING METHODS AND CONSTRUCTS | Fondazione Telethon ETS (IT) | 2026-02-25 | — | — | EP | claimed |
| US-20250288694-A1 | HOMOLOGY INDEPENDENT TARGETED INTEGRATION FOR GENE EDITING | FONDAZIONE TELETHON ETS (IT) | 2025-09-18 | — | — | US | claimed |
| US-20250222140-A1 | GENOME EDITING METHODS AND CONSTRUCTS | FONDAZIONE TELETHON ETS (IT) | 2025-07-10 | — | — | US | claimed |
| EP-4518907-A1 | HOMOLOGY INDEPENDENT TARGETED INTEGRATION FOR GENE EDITING | Fondazione Telethon ETS (IT) | 2025-03-12 | — | — | EP | claimed |
| CN-119136844-A | Homologous independent targeted integration for gene editing | 泰莱托恩基金会第三部门组织 | 2024-12-13 | — | — | CN | claimed |
| WO-2024216536-A1 | METHOD FOR PREPARING RIBONUCLEOSIDE OR DERIVATIVE THEREOF, AND BIOLOGICAL ENZYME PREPARATION AND APPLICATION THEREOF | 百瑞全球有限公司 | 2024-10-24 | — | — | WO | claimed |
| WO-2024218394-A1 | GENOME EDITING METHODS AND CONSTRUCTS | FONDAZIONE TELETHON ETS (IT) | 2024-10-24 | — | — | WO | claimed |
| EP-3542823-B1 | INTRACELLULAR ATP ENHANCER | STAGEN CO LTD (JP) | 2024-03-13 | — | — | EP | claimed |
| WO-2024048514-A1 | TESTING METHOD FOR CERVICAL CANCER AND/OR CERVICAL INTRAEPITHELIAL NEOPLASIA | 学校法人藤田学園 | 2024-03-07 | — | — | WO | claimed |
| WO-2023213831-A1 | HOMOLOGY INDEPENDENT TARGETED INTEGRATION FOR GENE EDITING | FONDAZIONE TELETHON ETS (IT) | 2023-11-09 | — | — | WO | claimed |
| EP-0813599-A1 | PLANT ADENYLOSUCCINATE SYNTHETASE AND DNA CODING THEREFOR | Novartis AG (CH) | 1997-12-29 | — | — | EP | claimed |
| US-5688939-A | Plant adenylosuccinate synthetase and DNA coding therefor | NOVARTIS FINANCE CORPORATION | 1997-11-18 | — | — | US | claimed |
| WO-1996034855-A1 | FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS | SCOTIA HOLDINGS PLC (GB) | 1996-11-07 | — | — | WO | claimed |
| WO-1996034846-A1 | 1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS | SCOTIA HOLDINGS PLC (GB) | 1996-11-07 | — | — | WO | claimed |
| WO-1996019576-A1 | PLANT ADENYLOSUCCINATE SYNTHETASE AND DNA CODING THEREFOR | NOVARTIS AG (CH) | 1996-06-27 | — | — | WO | claimed |
| WO-1996018739-A1 | PLANT ADENYLOSUCCINATE LYASE AND DNA CODING THEREFOR | NOVARTIS AG (CH) | 1996-06-20 | — | — | WO | claimed |
| US-5519125-A | Plant adenylosuccinate synthetase and DNA coding therefor | CIBA-GEIGY CORPORATION (US) | 1996-05-21 | — | — | US | claimed |
| EP-0458519-A2 | Synthesis of nucleotide and nucleoside derivatives | EFAMOL HOLDINGS PLC (GB) | 1991-11-27 | — | — | EP | claimed |
| EP-0286303-A1 | DNA and its use | Takeda Chemical Industries, Ltd. (JP) | 1988-10-12 | — | — | EP | claimed |
| US-4578336-A | ADENINE SOURCE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-03-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288694-A1 | HOMOLOGY INDEPENDENT TARGETED INTEGRATION FOR GENE EDITING | HAVCR2, HMGB3, FANCI | DNPH1 1156/4885P2RY12 3611/4885TAS1R3 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.